Resource use and costs INNOVATE Maintenance CSNS = OCS () Cost of £86.51 NHS exacerbations CSS = Reference £136.04 costs () PSSRU Unit costs () 2 per year, Routine visits NHS £160 each reference Initiation of costs () £245 therapy Standard INNOVATE therapy £1,197 () (per year) Omalizumab INNOVATE costs £8,056 () (per year) INNOVATE Administration year: () and £260 NHS monitoring Thereafter: reference costs £146 costs () Incorporation of OCS-related adverse effects Proportion of omalizumab 41.9% maintenance responders OCS () who
Resource use and costs Cost of exacerbations CSNS = £86.51 CSS = £136.04 INNOVATE Maintenance OCS () NHS Reference costs () PSSRU Unit costs () Routine visits 2 per year, £160 each NHS reference costs () Initiation of therapy £245 Standard therapy (per year) £1,197 INNOVATE () Omalizumab costs (per year) £8,056 INNOVATE () Administration and monitoring costs year: £260 Thereafter: £146 INNOVATE () NHS reference costs () Incorporation of OCS-related adverse effects Proportion of omalizumab responders who 41.9% maintenance OCS ()